Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation

Abstract

In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.

The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows: 
     
         1 . A method of treating a subject suffering from, or at risk of developing, an ischemia-reperfusion injury comprising administering to the subject a monoclonal MASP-2 inhibitory-antibody, or antigen-binding fragment thereof, that specifically binds to a portion of SEQ ID NO:6 and inhibits MASP-2-dependent complement activation 
     
     
         2 . The method of  claim 1 , wherein the MASP-2 inhibitory antibody, or antigen-binding fragment thereof, selectively inhibits MASP-2-dependent complement activation without substantially inhibiting C1q-dependent classical complement pathway activation. 
     
     
         3 . The method of  claim 1 , wherein the MASP-2 inhibitory monoclonal antibody, or antigen-binding fragment thereof, specifically binds to a portion of SEQ ID NO:6, wherein said portion does not include the CUBI-EGF-CUBII domains (amino acid residues 1-293 of SEQ ID NO:6). 
     
     
         4 . The method of  claim 1 , wherein the MASP-2 inhibitory monoclonal antibody, or antigen-binding fragment thereof, specifically binds to a polypeptide comprising SEQ ID NO:6 with an affinity of at least 10 times greater than it binds to a different antigen in the complement system. 
     
     
         5 . The method of  claim 1 , wherein the monoclonal antibody or antigen-binding fragment thereof is recombinant. 
     
     
         6 . The method of  claim 1 , wherein the monoclonal antibody, or antigen-binding fragment thereof, has reduced effector function. 
     
     
         7 . The method of  claim 1 , wherein the monoclonal antibody, or antigen-binding fragment thereof, is a chimeric, humanized or human. 
     
     
         8 . The method of  claim 1 , wherein the ischemia-reperfusion injury is associated with cardiopulmonary bypass. 
     
     
         9 . The method of  claim 1 , wherein the ischemia-reperfusion injury is associated with an organ transplant. 
     
     
         10 . The method of  claim 1 , wherein the ischemia-reperfusion injury is associated with extremity or digit replantation. 
     
     
         11 . The method of  claim 1 , wherein the ischemia-reperfusion injury is associated with myocardial infarction. 
     
     
         12 . The method of  claim 1 , wherein the ischemia-reperfusion injury is associated with gastrointestinal ischemia-reperfusion. 
     
     
         13 . The method of  claim 1 , wherein the ischemia-reperfusion injury is associated with hemodynamic resuscitation following shock or surgical procedures.